ArticleThe Journal of clinical and aesthetic dermatology2024
Vitiligo Exchange: An Expert Panel Discussion of Two Clinical Cases.
Article in The Journal of clinical and aesthetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article is based on a roundtable discussion in which three panelists review clinically relevant insights about vitiligo and discuss two cases that illustrate the multiple challenges faced by both patients and clinicians in managing this complex disease. The first is a 32-year-old White female patient with Fitzpatrick Skin Type III/IV with extensive depigmentation in the trunk area. The patient achieved 90-percent repigmentation with a combination therapy approach. Treatment included systemic corticosteroids, oral antioxidants, narrowband ultraviolet B phototherapy, and topical therapy initially with tacrolimus ointment followed by topical ruxolitinib cream. Patient counseling around variable rates of progressive repigmentation over time, the significance of combining therapeutic approaches, and the importance of treatment consistency are discussed. The second case is that of a White pediatric female patient with vitiligo, who was treated from the ages of 5 to 11 years, with a break in treatment due to the patient's desire to discontinue treatment. Once treatment recommenced, the patient ultimately achieved 75-percent repigmentation within six months using a combination of narrowband ultraviolet B phototherapy, topical corticosteroids, and topical calcineurin inhibitors. The emotional burden of pediatric vitiligo for patients and their caregivers are discussed, along with joint decision making with this patient and her parents. This was followed by a discussion of the significance of the patient's anti-nuclear antibody positivity and how this affects treatment approach in patients with vitiligo.
Indexed as
Identifiers
39830989PMC11740887What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.